No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
STTK240621P5000
- 0.06
- -0.21-77.78%
15min DelayClose Jun 14 12:30 ET
0.06High0.06Low
0.06Open0.27Pre Close10 Volume31 Open Interest5.00Strike Price60.00Turnover146.31%IV20.19%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type-0.1030Delta0.1586Gamma103.17Leverage Ratio-0.0174Theta-0.0001Rho-10.63Eff Leverage0.0014Vega
Intraday
- 5D
- 1D
News
BTIG Downgrades Shattuck Labs(STTK.US) to Hold Rating, Cuts Target Price to $5
BTIG analyst Kaveri Pohlman downgrades $Shattuck Labs(STTK.US)$ to a hold rating, and adjusts the target price from $12 to $5.According to TipRanks data, the analyst has a success rate of 25.8% and a
Shattuck Labs Is Maintained at Buy by Needham
Shattuck Labs Is Maintained at Buy by Needham
Assessing Shattuck Labs: Insights From 6 Financial Analysts
During the last three months, 6 analysts shared their evaluations of Shattuck Labs (NASDAQ:STTK), revealing diverse outlooks from bullish to bearish.The following table summarizes their recent ratings
Needham Maintains Shattuck Labs(STTK.US) With Buy Rating, Cuts Target Price to $8
Needham analyst Gil Blum maintains $Shattuck Labs(STTK.US)$ with a buy rating, and adjusts the target price from $12 to $8.According to TipRanks data, the analyst has a success rate of 41.0% and a tot
Express News | Shattuck Labs Inc : Needham Cuts Target Price to $8 From $12
Shattuck Gains on Early-stage Data Update for Lead Asset in Blood Cancer
Shares of Shattuck Labs (NASDAQ:STTK) traded higher premarket Friday after the company announced updated interim data from an early-stage trial for its lead candidate SL-172154 in combination with chemotherapy azacitidine in blood cancer.
Comments
$Shattuck Labs(STTK.US$ Shattuck Labs, Discloses Updated Interim Data From Phase 1B Dose Expansion Clinical Trial Of SL-172154 In Combination With Azacitidine In Frontline Higher-Risk Myelodysplastic Syndromes And TP53 Mutant Acute Myeloid Leukemia Patients
Benzinga
The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had no...
Benzinga
The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had no...
$Shattuck Labs(STTK.US$ Benzinga· 2 mins ago
Shattuck Labs Granted Orphan Drug Designation By FDA For SL-172154 In Acute Myeloid Leukemia
Shattuck Labs Granted Orphan Drug Designation By FDA For SL-172154 In Acute Myeloid Leukemia
1
$Shattuck Labs(STTK.US$
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
1
$Shattuck Labs(STTK.US$ Shattuck Labs Announces Drug Discovery Collaboration With Ono Pharmaceutical, For Bifunctional Fusion Proteins Targeting Certain Autoimmune And Inflammatory Disease Pathways, Shattuck To Receive Upfront And Be Eligible For Milestone Payments Of Upto $227M
Read more